Technology

Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation

Published

1 year ago

January 30, 2025

Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value

WEXFORD, Pa., Jan. 30, 2025 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, is excited to announce its rebranding to COEPTIS, marking a transformative shift in its business strategy. This pivotal change reflects our commitment to expanding beyond biopharmaceuticals and embracing diverse growth opportunities in technology-driven sectors.
With the establishment of our new Technology Division, COEPTIS aims to enhance operational capabilities and maximize shareholder value. Central to this initiative was the recent acquisition of the NexGenAI Affiliates Network platform, a groundbreaking AI-powered marketing solution. This acquisition aligns seamlessly with COEPTIS’s mission to innovate in highly regulated industries, revolutionizing marketing strategies and operational efficiencies.

By integrating NexGenAI’s advanced tools, COEPTIS empowers companies to tackle marketing challenges in competitive landscapes with AI-driven precision and efficiency. Building on this foundation, our Technology Division is expanding its automation capabilities and developing AI agents to optimize workflows and drive operational efficiency through intelligent automation.

Dave Mehalick, President and CEO of Coeptis, stated, “This strategic move not only reinforces our commitment to innovation but also strengthens our efforts to expand into revenue-generating, cash flow-positive business units. By leveraging cutting-edge technologies, we are positioning COEPTIS as a self-sustaining entity, creating a robust foundation for long-term growth and profitability.”

“NexGenAI Affiliates Network stands apart as a trailblazer in delivering practical, transformative AI solutions tailored for real-world business needs. Unlike traditional AI firms focused on narrow applications or theoretical advancements, Coeptis Technologies leverages a proprietary suite of advanced technologies; including AI-driven marketing software, robotic process automation (RPA), and actionable data analytics—to empower businesses across diverse sectors. Our platform is designed not just to automate processes, but to enhance communication strategies, optimize campaigns, and drive sustainable growth and we remain committed to responsible innovation harnessing the power of technology to create meaningful impact and deliver tangible value.” added Mr. Mehalick.

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively “Coeptis”), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.

The Company’s therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.

Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.

Headquartered in Wexford, PA, Coeptis is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on Coeptis, visit https://coeptistx.com.

Cautionary Note Regarding Forward-Looking Statements

This press release and statements of our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company’s securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company’s products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts
IR@coeptistx.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-holdings-becomes-coeptis-embracing-a-future-of-technology-and-innovation-302364358.html

SOURCE Coeptis Therapeutics, Inc.

Technology

Electrolux Group to end production in Jászberény, Hungary

Published

32 minutes ago

April 22, 2026

STOCKHOLM, April 22, 2026 /PRNewswire/ — Electrolux Group has decided to end production at the Jászberény, Hungary factory, which manufactures built-in and freestanding refrigeration products. Production is expected to cease by the end of 2026. A restructuring charge of approximately SEK 0.6 billion, of which SEK 0.3 billion is cash related, will be reported as a negative non-recurring item affecting operating income for Region Europe, Middle East & Africa and Asia-Pacific in the second quarter of 2026.

The decision follows a review of the company’s strategy to strengthen cost competitiveness and increase agility through production footprint optimization. This is driven by the current competitive environment, which is impacted by stagnant market demand, price pressure, and increasing constraints on cost competitiveness. The planned site closure will impact approximately 600 employees.

Electrolux Group will fully meet demand for refrigeration products by leveraging existing operations as well as working with external OEM partners. The decision does not affect the local sales and marketing activities managed by the Budapest office.

This is information that AB Electrolux is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 22-04-2026 08:30 CET.

For more information:

Ann-Sofi Jönsson, Head of Investor Relations & Sustainability Reporting, +46 73 025 1005

Maria Åkerhielm, Investor Relations Manager, +46 70 796 3856

Henry Sjölin, Investor Relations Manager, +46 76 863 51 85

Electrolux Group Press Hotline, +46 8 657 65 07

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/electrolux-group/r/electrolux-group-to-end-production-in-jaszbereny–hungary,c4337676

The following files are available for download:

https://mb.cision.com/Main/1853/4337676/4051089.pdf

Press release Hungary April 22 2026 ENG final

View original content:https://www.prnewswire.com/news-releases/electrolux-group-to-end-production-in-jaszbereny-hungary-302749943.html

SOURCE Electrolux Group

Technology

MediaGo and hipto Secure Another Les Cas d’Or Gold in Performance Marketing

Published

32 minutes ago

April 22, 2026

SAN FRANCISCO, April 22, 2026 /PRNewswire/ — Recently, MediaGo, a global intelligent advertising platform, and hipto, France’s premier lead generation specialist, won Gold in the “Content and Vertical Industries” category at the prestigious French digital marketing awards, Les Cas d’Or. Recognized for a benchmark performance marketing campaign in the health insurance sector, this award—voted on by over 40 brand marketing directors—serves as further authoritative validation of MediaGo’s technical prowess and service capabilities in the European market.

Following previous wins of Gold in the Native Advertising category and Bronze in the Banking & Insurance Acquisition category, this latest industry honor marks another significant milestone. It underscores that MediaGo’s localized native advertising capabilities, along with its ability to apply deep learning technologies in complex user acquisition scenarios across France and Europe, have earned high acclaim from both the market and industry experts, cementing its position at the forefront of the industry.

The French health insurance market is highly competitive and saturated. Local advertisers have long relied heavily on search and social media channels, resulting in persistently high CPAs and significant traffic inflation. Addressing these industry pain points, MediaGo and hipto collaborated to pioneer a new growth trajectory, establishing the open web as the third core acquisition pillar alongside search and social. By leveraging premium local news and information publishers in France, they seamlessly integrated native ads into media environments, providing the insurance sector with a scalable, replicable growth blueprint to effectively counter traffic inflation.

This award-winning campaign focused on scaling the acquisition of high-intent leads in the insurance sector. It successfully overcame three structural challenges inherent in traditional bidding models: reactive algorithms, high cold-start costs, and the difficulty of balancing scale with efficiency. This achievement further validates MediaGo’s strong operational capabilities and its innovation in native advertising within the French market.

Powered by five deep learning models and the newly upgraded SmartBid 3.0, MediaGo precisely predicts the conversion probability of each ad impression in real time. Paired with hipto’s high-frequency creative iterations (3–5 times per week), MediaGo continuously identifies high-potential audience clusters, further enhancing targeting precision. In addition, SmartBid 3.0’s unique “global learning” mechanism reduced the cold start learning cycle for new campaigns by 50%. This partnership enabled campaigns to achieve stable monetization from day one.

By utilizing SmartBid 3.0’s MaxCV mode, hipto’s campaigns achieved a dual breakthrough in both scale and efficiency. Data shows an immediate 32% uplift in monthly conversion volume and a threefold increase in lead volumes over the longer term, successfully expanding market share within a saturated vertical. Additionally, native ad CTR surpassed the industry benchmark by 53%, demonstrating the platform’s ability to precisely target high-intent users. Notably, even with a 48% increase in mobile budget allocation, CPA decreased by 2.6%, proving that volume scaling and margin preservation can coexist.

Leo Ye, Head of Partnerships at MediaGo, stated: “Winning the Les Cas d’Or Gold for Performance Marketing is a strong endorsement of MediaGo’s technical strength and localized service capabilities. We remain committed to a performance-driven, advertiser-centric approach, deepening our footprint in the French market to help advertisers break through growth bottlenecks in a saturated landscape.”

Looking ahead, MediaGo will continue to deepen its presence in Europe. With deep learning at its core, the platform aims to continuously enhance its native advertising capabilities and localized operations, delivering tangible value to global advertisers and empowering partners to achieve high-quality, sustainable business growth in complex market environments.

About MediaGo

MediaGo is a leading intelligent advertising platform. Based on deep learning algorithms, MediaGo empowers businesses of all scales, creating tangible value for companies. With 12 operational centers worldwide, MediaGo has successfully provided localized and comprehensive business growth services to over 10,000 partners.

Photo – https://mma.prnewswire.com/media/2961753/PRN.jpg

View original content:https://www.prnewswire.co.uk/news-releases/mediago-and-hipto-secure-another-les-cas-dor-gold-in-performance-marketing-302748643.html

Technology

Dandelion Civilization launches a Human Intelligence Platform to make talent risk visible before it becomes expensive

Published

33 minutes ago

April 22, 2026

New Human Intelligence Platform helps employers assess role fit, team dynamics, and early behavioral risk to avoid costly talent decisions.

AMSTERDAM, April 22, 2026 /PRNewswire/ — Dandelion Civilization today announced the launch of its Human Intelligence Platform at HR Tech Europe 2026, introducing a new approach to talent management and workforce decision-making, built around behavioral intelligence rather than instinct alone.

The launch addresses a problem many organizations already understand but still struggle to solve. Talent mis-matches are expensive, early misalignment is difficult to correct, and quality of hire remains hard to improve because the real consequences often appear months after a decision is made. Industry estimates frequently place the total cost of hiring a new employee at several times the position’s salary, especially when poor fit leads to replacement, lost productivity, and disruption.

While much of the HR technology market has focused on the hiring stage itself, Dandelion Civilization is taking a different route. The platform is designed to help employers understand how people are likely to perform in real conditions by revealing how they think, act, and interact across hiring, team development, and workforce risk.

At the core of the platform is a behavioral intelligence layer that creates continuous, evolving profiles of individuals and teams. Rather than relying only on CVs, interviews, or static questionnaires, Dandelion Civilization uses behavioral simulations to surface signals around decision making, collaboration, pressure response, and alignment. According to the company’s launch materials, the product is built around three core areas: hiring intelligence, team dynamics, and behavioral risk. It is designed to support decisions before day one, strengthen visibility into how individuals affect team performance, and identify patterns that may point to conflict, disengagement, or misalignment before those issues damage business outcomes.

“We are not creating another assessment tool,” said Dmitry Zaytsev, Founder and CEO of Dandelion Civilization. “We are building the infrastructure for better talent decisions. Companies often discover the true cost of misalignment too late, when trust weakens, performance slips, or the hiring process has to begin again. We want to make those signals visible earlier, when organizations can still act on them.”

The company says the platform is designed to fit into existing workflows without technical friction. Employers send a link, candidates complete an online simulation, and talent teams receive a decision-ready report. The launch deck states that the simulation takes around 20 to 40 minutes, requires no integration, and works in any browser.

While the platform begins with hiring, Dandelion Civilization is positioning the launch as the first step toward a broader layer of human capital intelligence that can support team design, talent development, and earlier visibility into people related risk over time.

About Dandelion Civilization
Dandelion Civilization is building a Human Intelligence Platform that helps organizations understand how people think, act, and interact across the employment lifecycle. Using behavioral simulations and digital profiling, the platform supports hiring, team development, and earlier visibility into workforce risk. Its launch materials describe the product as a system designed to reduce talent blind spots and reveal behavior beyond profiles.

View original content:https://www.prnewswire.co.uk/news-releases/dandelion-civilization-launches-a-human-intelligence-platform-to-make-talent-risk-visible-before-it-becomes-expensive-302748410.html